New GSK, with new ambitions for patients and shareholders
The following information relates to the formation of New GSK and how the company plans to drive growth and returns for shareholders. It is intended for those with a specific interest in this area.
Our CEO Emma Walmsley discusses our strategy for New GSK, the new growth company positioned to create significant value for patients and shareholders from 2022 and for the next decade.
We expect to deliver a step change in performance with major new commitments to sales and profit growth including more than 5% sales CAGR 2021-26, more than 10% adjusted operating profit CAGR 2021-26 expected and an ambition to deliver more than £33 billion sales by 2031. This transformation will be enabled by New GSK’s growth engine, Vaccines and Specialty Medicines, which we expect to grow to around three-quarters of our revenue base by 2026.
At GSK, we have already delivered unprecedented change over the past four years, improving R&D, becoming a leader in Consumer Health, strengthening our leadership and transforming our commercial execution. Now, we are making our most significant corporate change in more than 20 years, setting out a new ambition for creating value for shareholders and impacting the health of over 2.5 billion people over 10 years.
New GSK Investor update
Emma Walmsley, CEO, and other members of the GLT hosted a virtual investor update on 23 June 2021. The update provided a clear view of the strategy for New GSK, its outlook for growth and the opportunities we see for shareholder value creation.
Scroll down to watch the event and access the presentations, transcripts, press release and other supplementary information.
Clinical trials summary
Discover our latest financial performance announcement and search for historical quarterly results materials.
A summary of the progress we made in 2020 against our long-term priorities of Innovation, Performance and Trust, underpinned by a continuing shift in culture. Also access and download the full Annual Report or individual sections.
Global Headquarters (London, UK)
VP, Global Corporate Media Relations
Director, Global Corporate Media Relations, Pharmaceuticals
Director, Global Corporate Media Relations, Vaccines and Global Public Health
VP, Global Product & Pipeline Communications & US Corporate Communications
Head, US Corporate Communications